Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 3, 2025—The Diagnostic Medicine Consortium has officially launched, bringing together the Association for Pathology Informatics and Project Santa Fe Foundation and with the aim of adding other like-minded collaborating medical diagnostic societies.
Feb. 26, 2025—Q-linea announced that it has signed a second commercial contract for its ASTar instrumentation in the United States.
Feb. 25, 2025—Labcorp announced that its Labcorp Plasma Complete is now available for clinical use.
Feb. 24, 2025—Roche unveiled a proprietary sequencing by expansion (SBX) technology that offers ultra-rapid, high-throughput sequencing that is flexible and scalable for a broad range of applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing.
Feb. 18, 2025—Roche announced that its Roche Elecsys sFlt-1/PlGF ratio for preeclampsia has received FDA 510(k) clearance.
Feb. 12, 2025—BioMérieux announced that its BioFire FilmArray Gastrointestinal (GI) Panel Mid has obtained FDA clearance.
Feb. 11, 2025—Ibex Medical Analytics has received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic, software only medical device that analyzes scanned histopathology whole slide images from prostate core needle biopsies prepared from H&E-stained formalin-fixed, paraffin-embedded tissue.
Feb. 10, 2025—Leica Biosystems announced the next iteration in its staining and coverslipping portfolio, the HistoCore Chromax Workstation.
Feb. 7, 2025—The FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with unresectable or metastatic HR-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting.
Feb. 3, 2025—The Food and Drug Administration approved a label expansion for the Roche Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone-receptor-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with Enhertu.
